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Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entityaccounting for 1-2% of AML cases. A substantial proportion of thesepatients have a concomitant FLT3-ITD. While outcomes are dismal
with intensive chemotherapy, limited evidence suggests allogeneic
hematopoietic cell transplantation (allo-HCT) may improve survival if per-
formed early during first complete remission. We report on a cohort of 178
patients with t(6;9)(p22;q34) within an international, multicenter collabora-
tion. Median age was 46 years (range: 16-76), AML was de novo in 88%,
FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in
21%. Complete remission was achieved in 81% (n=144), including 14
patients who received high-dose cytarabine after initial induction failure.
With a median follow up of 5.43 years, estimated overall survival at five
years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%)
patients, including 89 in first complete remission. Allo-HCT in first com-
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plete remission was associated with higher 5-year relapse-free and overall survival as compared to consoli-
dation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and
23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall
survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second
[58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%);
n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclu-
sion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with
allo-HCT.  
Introduction
Acute myeloid leukemia (AML) with t(6;9)(p22;q34) has
been listed as a distinct entity in the World Health
Organization classification since 2008 and accounts for a
small group (1-2%) of AML patients.1,2 The translocation
t(6;9), first described in AML in 1976,3 results in formation
of the DEK-NUP214 chimeric fusion gene, where DEK at
6p223 is fused to NUP214 (formerly known as CAN),
located at 9q34.4 This fusion gene acts as an aberrant tran-
scription factor and alters nuclear transport by binding sol-
uble transport factors.5 In addition, DEK-NUP214 has
been reported to enhance protein synthesis in myeloid
cells.6,7 In a murine model, DEK-NUP214 induced
leukemia when transduced to long-term repopulating
stem cells.8
Acute myeloid leukemia with t(6;9) occurs in children
and adults, as reported in a retrospective cohort analysis of
69 patients (31 children and 38 adults) with a median age
of 23 years, most of whom presented with de novo AML.2
Of note, 42-69% of pediatric and 73-90% of adult AML
patients with t(6;9) are described to harbor a concomitant
internal tandem duplication of the FLT3 gene (FLT3-
ITD),2,9-13 while secondary cytogenetic abnormalities are
observed in 12-19% of pediatric and adult patients.2,13
Clinically, t(6;9) AML has been associated with a poor
prognosis in children and adults,2,12-15 with reported 5-year
overall survival (OS) rates of 28% and 9%, respectively.2
With this, adult patients with this translocation are catego-
rized into the adverse risk group according to the National
Comprehensive Cancer Network guidelines.16 Allogeneic
hematopoietic cell transplantation (allo-HCT) may
improve survival if performed during first complete remis-
sion (CR1).2,17 However, the results were hampered by the
small number of patients. Even results derived from a large
registry data base were inconclusive on this issue due to
missing data on allo-HCT.15 Additionally, results on AML
patients with t(6;9)(p22;q34) are rarely reported, although
these patients were included in a recent large randomized
trial.18 Thus, international multicenter cohort studies are
the only opportunity to better describe characteristics and
evaluate outcome according to treatment strategies.  
The objectives of our study were to characterize a large
cohort of AML patients with t(6;9)(p22;q34) in an interna-
tional, multicenter cohort and to evaluate outcomes
according to treatment.
Methods
Patients and treatment
Information on 178 patients with AML and t(6;9)(p22;q34)
diagnosed between 1989 and 2016 was collected from fourteen
study groups/institutions in the US and Europe. Participating cen-
ters were chosen upon network relationships of the first and last
author. Detailed case report forms (including information on
baseline characteristics, chemotherapy, allo-HCT, response, and
survival) were collected from all participating centers. Inclusion
criteria were adult patients with t(6;9)(p22;q34), eligible for inten-
sive therapy (ECOG 0-2), including (but not limited to) allo-HCT.
All patients who fulfilled these criteria were included by the par-
ticipating groups/institutions, respectively. Diagnosis of AML
was based on French-American-British Cooperative Group crite-
ria19 and, after 2003, on revised International Working Group cri-
teria.20 Chromosome banding was performed using standard
techniques, and karyotypes were described according to the
International System for Human Cytogenetic Nomenclature.21
FLT3 mutation screening for internal tandem duplications (ITD)
and point mutations within the tyrosine kinase domain (TKD)
was carried out at each institution per local practice.10,22 Data col-
lection and analysis were approved by the Institutional Review
Boards of the participating centers.
Treatment
One-hundred and seventy-six of the 178 patients (99%)
received intensive induction treatment either within clinical trials
(n=116) or according to local institutional standards (n=62).
Treatment protocols included the Study Alliance Leukemia (SAL)
AML9623 and AML200324 trials, the United Kingdom AML10,15
AML11,25 AML12,15 AML14,25 AML15,15 AML1626 and AML1727
protocols, as well as the ALFA 9801,28 980229 and 070230 trials.
Induction therapy according to local standard most frequently
consisted of the 7+3 regimen of anthracycline plus cytarabine
(n=53). Two patients (1%) received either azacitidine or
decitabine as induction therapy and both went on to allo-HCT.
Response was assessed according to International Working
Group recommendations.20 All studies were approved by the
institutional review boards of the participating centers. All
patients provided written informed consent for participation in
one of the treatment trials or for therapy according to local stan-
dards. 
Statistical analysis
Survival end points including OS, relapse-free survival (RFS),
cumulative incidence of relapse (CIR), and cumulative incidence
of death in CR (CID) were defined according to the revised rec-
ommendations of the International Working Group.20
Comparisons of patients' characteristics were performed with
the Kruskal-Wallis rank sum test for continuous variables and
Fisher’s exact test for categorical variables. The median follow-up
time was computed using the reverse Kaplan-Meier estimate.31
The Kaplan-Meier method was used to estimate the distribution
of RFS and OS.32 Confidence interval (CI) estimation for survival
curves was based on the cumulative hazard function using
Greenwood’s formula for variance estimation. Log rank tests
were employed to compare survival curves between groups. A
Cox proportional hazards regression model was used to identify
prognostic variables for OS.33 The following variables were
included in the Cox models: age at diagnosis, gender, logarithm
of white blood cells, platelet count, FLT3-ITD mutational status,
and detection of additional cytogenetic abnormalities. The effect
of allo-HCT on OS as a time-dependent intervening event was
tested by using the Mantel-Byar method34 for univariable and
Andersen-Gill model for multivariable analyses.35 The method of
Simon and Makuch was used to estimate survival distributions
with respect to time-dependent interventions.36
The individuals at risk were initially all represented in the
chemotherapy group. If patients received an allo-HCT, they were
censored at this time point in the chemotherapy group and fur-
ther followed up within the allo-HCT group.  
Cumulative incidence of relapse and CID and their standard
errors were computed according to the method described by
Gray37 and included only patients attaining CR. Missing data
were replaced by 50 imputations using multivariate imputations
by chained equations applying predictive mean matching.38
Backward selection applying a stopping rule based on P-values
was used in multivariable regression models to exclude redun-
dant or unnecessary variables. All statistical analyses were per-
formed with the  R statistical software environment, version
3.3.1, using the R packages prodlim, version 1.5.7, and survival,
version 2.39-5.39
Results
Study cohort
Overall demographic and clinical data were collected
from 178 patients (MRC, n=75; SAL, n=27; Fred
Hutchinson Cancer Research Center, Seattle, n=12; ALFA,
n=12; Dana-Faber Cancer Institute and Massachusetts
General Hospital, Boston, n=12; Johns Hopkins
University, Baltimore, n=8; Charité-University Medical
Center Berlin, n=7; University of Maryland Greenebaum
Comprehensive Cancer Center, n=6; Memorial Sloan
Kettering Cancer Center, New York, n=6; Perelman School
of Medicine at the University of Pennsylvania, n=4; Mayo
Clinic Rochester, n=4; Czech Leukemia Centers, n=4;
University Hospital Bonn, n=1) diagnosed with
t(6;9)(p22;q34) AML between 1989 and 2016. Baseline
characteristics are summarized in Table 1; median age was
46 years (range: 16-76) and 82 patients (46%) were female.
Type of AML was de novo in 157 (88%), therapy-related in
4 (2%), and secondary after previous myelodysplastic syn-
drome (MDS)/myeloproliferative neoplasm in 12 (7%)
patients. In addition, five (3%) patients with MDS treated
intensively according to AML protocols were included in
this analysis. Median white blood cell (WBC) count was
16.6x109/L (range: 0.5-274) and was significantly higher in
patients with, compared to without, FLT3-ITD (P=0.02). 
Cytogenetic and molecular analyses
The balanced translocation t(6;9)(p22;q34) was the sole
abnormality in 140 (79%) patients, while additional cyto-
genetic abnormalities were present in 38 (21%). Of note,
trisomy 13 was present in ten patients, either as a sole
additional abnormality (n=1), in combination with tri-
somy 8 (n=2) or with another balanced translocation
(n=2), or within a complex karyotype characterized by
gains only (n=5). FLT3-ITD molecular testing was avail-
able in 127 (71%) patients and 79 (62%) had FLT3-ITD.
FLT3-TKD mutational status was available in 76 (43%)
and 4 (5%) were mutated (Table 1). 
Response to induction therapy
Data on response to induction therapy were available in
all patients. Early death (ED) occurred in two (1%)
patients. Overall, CR was achieved in 144 patients (81%).
Thirty-five patients with initial induction failure received
a salvage therapy [high-dose cytarabine (HiDAC-)-based,
n=23; other intensive, n=3; not intensive, n=4; unknown,
n=5)] and 23 of them achieved a CR (66%), including 14
after HiDAC. The CR rate in patients with FLT3-ITD was
81% (64 of 79 patients) as compared to 77% (37 of 48
patients) in patients without FLT3-ITD (P=0.65). No prog-
nostic factors for CR achievement were identified within
the available baseline characteristics. Two of five patients
with MDS achieved a CR according to AML criteria. In six
patients with FLT3-ITD treated on the AML15 (n=2) or
AML17 (n=4) trials, lestaurtinib40 was added to induction
therapy and all patients achieved a CR.
Further therapy including intensive consolidation and
allogeneic hematopoietic stem cell transplantation
Fifty-five (38%) of 144 patients in CR1 received inten-
sive consolidation chemotherapy without transplantation,
whereas 89 (62%) proceeded to allo-HCT. The majority of
the patients (n=52 of 89, 58%) who went on to allo-HCT
received a consolidation therapy prior to transplant.
Relapses occurred in 47 (85%) patients after consolida-
tion chemotherapy and in 28 (31%) after allo-HCT in
CR1. Relapsed patients without allo-HCT died after in
median 5.4 months (range: 1-31.6 months). Twenty-one
patients who relapsed after allo-HCT died. 
Three patients died after consolidation chemotherapy
and seventeen in CR after allo-HCT in CR1, mainly due to
graft-versus-host disease (GvHD; n=5) or infections (n=4).
Tyrosine kinase inhibitors (TKI) were given after relapse
in seven patients with FLT3-ITD, either as single agents
(n=6) or in combination with chemotherapy (n=1) (post
allo-HCT, n=4; post chemotherapy, n=3). A CR2 was
achieved in one patient after treatment with gilteritinib41
and a second patient achieved CR2 with incomplete
hematologic recovery (CRi) after treatment with lestaur-
tinib in combination with mitoxantrone/etoposide/cytara-
bine. The first patient died in CR one month after 
initiation of gilteritinib due to a perforated intestine and
sepsis. The second patient relapsed six months after
achieving CR2 and received donor lymphocytes, but died
six months later due to progressive disease. Another
patient was salvaged with quizartinib and achieved a par-
tial remission (9% blast cells in bone marrow). The patient
then went on to allo-HCT, but died one month later due
to GvHD. Treatment with either gilteritinib or sorafenib
was not successful in the other four patients.
Allogeneic hematopoietic stem cell transplantation in
second complete remission 
Among patients not proceeding to allo-HCT in CR1, ten
patients were transplanted in CR2. Of those, six have died
at a median of 16.5 months after allo-HCT. Causes of
death in CR were infection (n=2), graft failure (n=1),
multi-organ failure (n=1), and unknown (n=1). One
patient relapsed and died due to AML. 
Allogeneic hematopoietic stem cell transplantation
with residual disease
In 34 patients not achieving a CR after intensive induc-
tion therapy, 15 (44%) proceeded to allo-HCT with active
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disease. Of those, six patients are still in CR after a median
follow up of 66.5 months (range: 11.8-110.8 months) and
two patients achieved CR2 after relapse and are still in CR,
whereas seven patients died (transplant-related mortality,
n=4; refractory AML after relapse, n=2; pulmonary
embolism 7.9 years after transplant, n=1). 
Allogeneic hematopoietic stem cell transplantation
after relapse
Three patients proceeded to allo-HCT with active dis-
ease after relapse and all of these patients died. Causes of
death included infection after 56 days in one and GvHD
15 days after transplant in another patient. One patient
died due to refractory AML after relapse.
Characteristics of patients undergoing allogeneic
hematopoietic stem cell transplantation
Overall, an allo-HCT was performed in 117 of the 178
patients (66%), either in CR1 (n=89) or CR2 (n=10), with
refractory disease (n=15) or after relapse (n=3) with no
differences in baseline characteristics between groups
(Table 1).
The majority of patients (n=76) received myeloablative
conditioning, including total body irradiation (TBI) in 39
S. Kayser et al.
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Table 1. Baseline characteristics of patients with acute myeloid leukemia and t(6;9)(p22;q34).
                                                                               All patients                                Subset of patients                            Subset of patients 
                                                                                  (n=178)                            undergoing allo-HCT in CR               undergoing allo-HCT with
                                                                                                                                          (n=99)                          active disease/ relapse (n=18)
Median age (years) (Range)                                                     46                                                               43                                                                46 
                                                                                                     (16-76)                                                      (16-71)                                                       (19-69)
Male gender, n (%)                                                                 96 (54)                                                      57 (58)                                                        9 (50)
Median WBC, x109/L (Range)                                                   16.6                                                            13.1                                                            16.3 
                                                                                                   (0.5-274)                                                   (0.5-274)                                                  (1.5-200.4)
Missing                                                                                            12                                                                 8                                                                   1
Median hemoglobin, g/dL (Range)                                          8.6                                                              8.6                                                                 9 
                                                                                                   (3.2-14.2)                                                  (3.2-14.2)                                                   (4.6-13.1)
Missing                                                                                            29                                                                18                                                                  2
Median platelets, x109/L (Range)                                             53                                                               53                                                                59 
                                                                                                     (7-451)                                                      (7-451)                                                      (10-229)
Missing                                                                                            21                                                                13                                                                  2
Median BM blasts, % (Range)                                                  60                                                               55                                                                60 
                                                                                                     (7-100)                                                     (10-100)                                                       (7-90)
Missing                                                                                            22                                                                12                                                                  1
Cytogenetics, n (%)                                                                                                                                                                                                         
As sole aberration                                                                140 (79)                                                     79 (80)                                                       14 (78)
Including +13*                                                                        10 (6)                                                          6 (6)                                                               -
Sole +13                                                                                      1                                                                 -                                                                  -
+ 8, +13                                                                                       2                                                                  1                                                                  -
Other complex**                                                                   11 (6)                                                          6 (6)                                                           1 (6)
Nullisomy X/Y                                                                            4 (2)                                                              -                                                              2 (11)
Other+                                                                                       13 (7)                                                          7 (7)                                                           1 (6)
Disease type, n (%)                                                                                                                                                                                                         
De novo AML                                                                         157 (88)                                                     88 (89)                                                       15 (83)
s-AML                                                                                      12 (7)                                                          7 (7)                                                           1 (6)    
t-AML                                                                                        4 (2)                                                           3 (3)                                                               -
MDS                                                                                          5 (3)                                                           1 (1)                                                          2 (11)
FLT3-ITD                                                                                                                                                                                                                              
n (%)                                                                                      79 (62)                                                      43 (57)                                                        9 (60)
Missing                                                                                       51                                                                25                                                                  3
FLT3-TKD                                                                                                                                                                                                                              
n (%)                                                                                        4 (5)                                                           4 (8)                                                               -
Missing                                                                                      102                                                               48                                                                  9
allo; allogeneic; AML:  acute myeloid leukemia; BM:  bone marrow; CR:  complete remission; FLT3:  fms-related tyrosine kinase 3; HCT:  hematopoietic cell transplantation; ITD:
internal tandem duplication; s-AML:  AML after previous myelodysplastic syndrome / myeloproliferative neoplasm; t-AML: therapy-related AML; TKD: tyrosine kinase domain;
WBC: white blood cell count. *Within a complex karyotype characterized by gains only (n=5). **Within a complex karyotype characterized by losses and unbalanced translo-
cations. +Other than +8/+13/nullisomy X/Y. Results may not add-up to 100 due to rounding.
patients. Forty-one patients received reduced-intensity
conditioning. Source of donor was matched related in 46,
matched unrelated in 54, haplo-identical in 11, cord blood
in five, and unknown in one of the 117 patients. 
Cumulative incidence of relapse, cumulative incidence
of death in complete remission and survival
The median follow up of the entire cohort was 5.43
years (95%CI: 3.93-6.53 years). Median and 5-year OS of
the entire cohort were 2.25 years (95%CI: 1.56-3.70
years) and 38% (95%CI: 31-47%). Five-year RFS and OS
were 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%)
in patients proceeding to allo-HCT in CR1 after induction
therapy (n=89), as compared to 7% (95%CI: 3-19%;) and
23% (95%CI: 13-38%), respectively, in those who
received consolidation chemotherapy alone (n=55) (Table
2). In subgroup analysis, presence of FLT3-ITD had no
prognostic impact on OS, either in the total analyzed
cohort (P=0.093), or in those patients proceeding to allo-
HCT (P=0.39). Similarly, additional chromosomal abnor-
malities had no prognostic impact on OS in the men-
tioned cohorts (P=0.49; P=0.86; respectively). A Cox
regression analysis revealed, after limited backward selec-
tion, higher WBC [hazard ratio (HR) for log10, 1.62;
95%CI: 1.12-2.29; P=0.005] and age (HR for a difference
of 10 years, 1.29; 95%CI: 1.12-1.50; P=0.001) as unfavor-
able variables, whereas platelet count, type of AML (de
novo vs. therapy-related/secondary after previous
MDS/myeloproliferative neoplasm), presence of FLT3-
ITD, and additional cytogenetic aberrations had no
impact on prognosis. 
In 144 patients achieving CR1, CIR was significantly
lower in patients proceeding to allo-HCT (n=89) as com-
pared to those who were treated with consolidation
chemotherapy (n=55; P<0.001). As expected, CID tended
to be higher in patients proceeding to allo-HCT as com-
pared to those receiving consolidation chemotherapy
(P=0.08) (Figure 1). 
One hundred and seventeen patients proceeded to allo-
HCT in CR1 (n=89) or CR2 (n=10), or with refractory
(n=15) or relapsed (n=3) disease. The influence of allo-
HCT assessed as a time-dependent co-variable as post
remission therapy on OS is illustrated by a Simon
Makuch plot (Figure 2). In addition, Figure 3 shows a
Kaplan Meier plot illustrating the influence of allo-HCT
performed in CR1 on RFS. The Mantel-Byar tests
revealed a significantly better OS (P=0.001) and RFS
(P<0.0001) for patients proceeding to allo-HCT in CR1 as
compared to consolidation with chemotherapy only.
Neither type of conditioning (P=0.90) nor donor type
(matched related donor versus matched unrelated/hap-
loidentical/cord blood donor; P=0.30) had an impact on
outcome. There was no difference in OS measured from
date of transplant in patients transplanted in CR1 or CR2
as compared to those with active disease  (P=0.66) (Figure
4). An Andersen-Gill model including allo-HCT as a time-
dependent variable revealed higher WBC and older age as
unfavorable variables, whereas allo-HCT performed
either in CR or with active disease was associated with a
favorable prognosis. Decade of treatment, additional
chromosomal abnormalities or FLT3-ITD had no prog-
nostic impact (Table 3).
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Figure 1. Cumulative incidence of relapse (CIR)
and cumulative incidence of death (CID) according
to treatment strategy. CIR and CID included only
patients achieving complete remission. 
Table 2. Relapse-free and overall survival according to treatment strategy in first complete remission.
                                                                                       5-years RFS %                        95%-CI                      5-year OS %                    95%-CI
Allo-HCT (n=89)                                                                                       45                                          35-59                                      53                                   42-66
Consolidation chemotherapy                                                                  7                                            3-19                                       23                                   13-38 
(n=55)                                                                                                           
allo-HCT: allogeneic hematopoietic cell transplantation; CI: confidence interval; OS: overall survival; RFS: relapse-free survival. Median follow up was 5.43 years (95%CI: 3.93-6.53
years). 
Discussion
The focus of our study was to characterize adult AML
patients with t(6;9) in an international cohort study and
compare outcomes according to treatment strategies, with
a specific focus on the impact of FLT3 mutations as well as
the impact of allo-HCT as compared to conventional
chemotherapy on survival. 
We studied 178 patients (AML, n=173; MDS, n=5), all
harboring the balanced translocation t(6;9)(p22;q34). A
concomitant FLT3-ITD has been described in 42-69% of
pediatric and 62-90% of adult AML patients with t(6;9),2,9-
13,42 but these reports were hampered by the availability of
mutational status in only a subset of patients2,9,42 and/or
analysis of a low patient number.9-12 In our large cohort,
with available mutational status in 71% of patients, a con-
comitant FLT3-ITD was detected in 62% and was signifi-
cantly associated with higher WBC at diagnosis, which
adds to previously published data.2,9-13,42 Preliminary data
suggest that FLT3-ITD promotes leukemia induction by
DEK-NUP214 in a murine model.43 However, a synergistic
effect to explain the high coincidence of the two muta-
tions has yet to be demonstrated. In contrast, FLT3-TKD
mutations were uncommon in our cohort and were slight-
ly less frequent than those reported in AML with normal
cytogenetics.44 In addition, secondary cytogenetic abnor-
malities were present in 21% of our patients, most com-
monly including trisomy 13, and/or trisomy 8, or a com-
plex karyotype. To date, there are still conflicting data
regarding the impact of FLT3-ITD on outcome in AML
patients with t(6;9).13,14,45 While results of a meta-analysis in
50 adult patients indicated an association between 
FLT3-ITD mutations and an inferior outcome in t(6;9)
AML,45 others were inconclusive due to the low number
of patients without FLT3-ITD,2 or did not find a significant
adverse impact in pediatric AML patients,13,14 which may
be due to an already very dismal prognosis.14 In our large
cohort, neither a concurrent FLT3-ITD nor the presence of
additional cytogenetic abnormalities had an impact on the
achievement of CR or OS, which adds to the recent eval-
uation by the European Society for Blood and Marrow
Transplantation (EBMT).42 
Previous publications in adult AML patients with t(6;9)
reported a fairly low CR rate of 33-58% in adult
patients.2,46 In contrast to these reports, we observed a
high CR rate of 81%. The favorable CR rate in our cohort
after intensive chemotherapy was in part due to a high
response rate of 66% after intensive salvage chemothera-
py in patients with failure after standard induction thera-
py. Intensive combination chemotherapy that incorpo-
rates higher doses of cytarabine is frequently used in
patients with relapsed/refractory AML, but no specific sal-
vage regimen has emerged as standard. While CR/CRi
rates with intensive combination chemotherapy were
overall below 40% and nearly similar in refractory (36%)
and relapsed AML (36.8%),47,48 the observed CR rate of
66% in our cohort points to a high sensitivity towards
higher doses of cytarabine in patients with initial induc-
tion failure. Particularly patients with adverse-risk cytoge-
netics or FLT3-ITD were shown to benefit from HiDAC
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Table 3. Multivariable Andersen-Gill model on overall survival.
                                                          HR (95%-CI)                   P
FLT3-ITD*                                                  1.35 (0.80-2.27)                   0.26
Log10(WBC)*                                           1.69 (1.14-2.51)                  0.009
Platelets (10x109/L difference)            1.00 (0.95-1.04)                   0.92
Female gender                                         1.43 (0.96-2.13)                   0.08
Age (10 years difference)                     1.22 (1.05-1.42)                   0.01
Type of AML#                                             0.83 (0.44-1.56)                   0.55
Additional abnormalities                        1.09 (0.67-1.77)                   0.74
Decade**                                                   0.81 (0.58-1.13)                   0.22
Transplant status                                     0.55 (0.33-0.90)                   0.02
AML: acute myeloid leukemia; CI: confidence interval; HR: hazard ratio; ITD: internal
tandem duplication; OS: overall survival; WBC: white blood cell count. *Sensitivity
analysis revealed no significant interaction between transplant status and FLT3-ITD
(P=0.44) or WBC (P=0.12) **Decade, 1989-1999, 2000-2009, 2010-2016. #Type of AML
denotes: de novo versus therapy-related/secondary after previous myelodysplastic syn-
drome/myeloproliferative neoplasm.
Figure 2. Simon Makuch plot evaluating the impact of allogeneic 
hematopoietic cell transplantation (allo-HCT) assessed as a time-dependent
co-variable in comparison with chemotherapy consolidation on overall survival.
Figure 3. Kaplan Meier plot illustrating the influence of allogeneic hematopoi-
etic cell transplantation (allo-HCT) performed in first complete remission on
relapse-free survival.
therapy.49 Therefore, the HiDAC approach might be 
beneficial in patients with t(6;9) and should be addressed
further. 
In addition, anthracycline dose intensification during
induction therapy with daunorubicin at 90 mg/m² has
been shown to have a beneficial impact,27 not only in
patients with core-binding factor leukemia,50 but also in
patients with FLT3-ITD.27,51 Although our analysis includ-
ed patients from the AML17 trial (n=22), which studied
high-dose daunorubicin, no meaningful analysis could be
made due to the low number of patients. 
In our analysis, we found that allo-HCT resulted in an
excellent RFS and OS, which is in line with the data of
Ishiyama et al.17 In a matched-pair analysis of de novo AML
using data from the Japanese allo-HCT data registry, they
compared outcome of 57 patients with t(6;9) to that of 171
patients with normal karyotype.17 All patients received an
allo-HCT between 1996 and 2007, either in CR1 or CR2
(n=116), or with active disease (n=112). In patients with
t(6;9), the 5-year OS (45% vs. 40%), disease-free survival
(42% vs. 33%), CIR (42 vs. 45%), and non-relapse mortal-
ity (16 vs. 22%) did not differ from those observed in AML
with normal karyotype.17 Nevertheless, the results were
hampered by a lack of molecular profile in the group of
AML with normal karyotype, as well as lack of data on
FLT3-ITD mutational status in AML with t(6;9). Our data
are particularly impressive when compared to the dismal
survival of patients with t(6;9) disease treated with
chemotherapy alone. Thus, allo-HCT seems to ameliorate
outcome in patients with t(6;9), with outcomes compara-
ble to those of patients with intermediate-risk cytogenet-
ics.52 As expected, CIR was significantly reduced in our
cohort after allo-HCT performed in CR1 as compared to
intensive consolidation chemotherapy. 
Since supportive care might have impacted outcome,
we have included the decade of treatment in multivariable
analysis. However, this had no impact on overall survival.
In addition, neither type of conditioning nor donor type
had any impact on outcome. Outcome after allo-HCT was
also favorable if performed in CR2, or even with active
disease. Overall, this suggests the existence of a specific
and very strong graft-versus-leukemia effect in this molec-
ular context. Of note, recently presented data by Beya et
al. on behalf of the EBMT demonstrated similar efficacy of
allo-HCT in AML with t(6;9) transplanted in CR2 or active
(relapsed/refractory) disease.42 Although this partly sup-
ports the finding from our cohort, we would like to
emphasize that retrospectively collected data have serious
limitations since the factors for allocating patients to allo-
HCT, such as co-morbidities, individual assessment of the
treating physician, choice of conditioning, and availability
of a donor, remain unknown, and this needs to be taken
into account when evaluating the value of allo-HCT in our
series.
Despite the large number of patients with FLT3-ITD,
only thirteen patients were treated with TKI, either front-
line with lestaurtinib (n=6) in combination with intensive
induction chemotherapy,40 or after relapse either with sin-
gle-agent gilteritinib41 or sorafenib (n=6), or with lestaur-
tinib in combination with intensive chemotherapy (n=1).
Interestingly, all six patients who received front-line
lestaurtinib + chemotherapy achieved a CR, whereas TKI
treatment ± chemotherapy in relapsed patients showed
limited efficacy, with only two patients achieving CR2.
Currently, midostaurin is the only approved TKI in de novo
AML with FLT3 mutations, based on the positive results
from the large, international randomized phase III trial.18
The combination of midostaurin with intensive
chemotherapy significantly improved OS in younger
adults with FLT3-mutated AML, as compared to the place-
bo arm. In that study, patients receiving an allo-HCT in
CR1 had a better outcome if they were treated with
midostaurin during induction therapy, suggesting that the
optimal treatment strategy in FLT3-mutated AML would
be to move on to allo-HCT early in CR1.18 Unfortunately,
no data were presented either in the manuscript or in the
supplement for the small subgroup of patients character-
ized by t(6;9).18 Thus, the impact of adding TKI to induc-
tion chemotherapy in t(6;9) AML is currently unknown. 
Conclusions
Our cohort of AML patients with t(6;9)(p22;q34)
showed a high CR rate after intensive induction therapy,
suggesting that these patients should be candidates for
intensive induction therapy whenever possible. Despite
the initial high chemo-sensitivity of the disease, treatment
with consolidation chemotherapy alone resulted in dismal
survival outcomes. Thus, based on our encouraging results
with allo-HCT, this should be standard of care whenever
possible for these patients.
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Figure 4. Overall survival after allogeneic hematopoietic cell transplantation
according to remission status.
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